

The following Listing of the Claims will replace all prior versions and all prior listings of the claims in the present application:

Listing of The Claims:

1. (Currently Amended) A composition comprising a an isolated non-Goodpasture fragment of $\alpha 3(\text{IV})$ NC1 domain ~~and comprising, wherein said fragment has~~ amino acid residues 185-203 of SEQ ID NO:10, ~~having~~ and at least one of the following activities:
 - (a) an ability to bind $\alpha_v\beta_3$ integrin; and
 - (b) an ability to inhibit proliferation of tumor cells; anda pharmaceutically-acceptable carrier.
2. (Previously Amended) The composition of Claim 1, wherein the ability to bind $\alpha_v\beta_3$ integrin is RGD-independent.
3. (Previously Amended) The composition of Claim 2, wherein the tumor cells are melanoma cells.
4. (Previously Amended) An isolated fragment of $\alpha 3(\text{IV})$ NC1 domain, having the amino acid sequence of amino acid residue 53 to amino acid 123 of SEQ ID NO:10.

Claims 5-8 canceled.

9. (Currently Amended) An isolated fragment of $\alpha 3(\text{IV})$ NC1 domain, having the amino acid sequence of amino acid residue ~~180~~181 to amino acid residue ~~245~~244 of SEQ ID NO:10.